Risk stratification tools are frequently used to help guide treatment decisions after first relapse in multiple myeloma. Researchers have developed a new risk stratification tool consisting of 4 distinct dimensions that is used to characterize survival expectations.
Researchers report the results of a phase 2 study evaluating the tolerability and long-term outcomes using a combination of ixazomib plus cyclophosphamide and low-dose dexamethasone in newly diagnosed multiple myeloma (MM) patients who are not eligible for transplant.
Adherence to prescribed therapy is pivotal in cancer treatment. To ensure that patients receive the full benefit of their prescribed therapy, nurses and nurse practitioners play a critical role in identifying adverse events and implementing effective interventions that balance efficacy and tolerability.
Researchers reported long-term follow-up results of the HOVON-65/GMMG-HD4 trial that evaluated survival outcomes with bortezomib-based induction and maintenance regimens followed by high-dose melphalan and autologous stem-cell transplantation in transplant-eligible patients with newly diagnosed multiple myeloma (MM) compared with the standard regimen. The impact of the bortezomib-based regimen on survival in the high-risk cytogenetic and renally impaired subset of patients was also reported.
The VISTA study demonstrated good tolerability of VMP; however, in a subsequent phase 2 trial, there was a higher rate of treatment discontinuation than expected. In this study, investigators demonstrated lowering the intensity of VMP proved to be both safe and effective for newly diagnosed multiple myeloma (NDMM).
Researchers examined subset of elderly newly diagnosed myeloma patients from the GEM2010 trial and split the patients into 2 arms determined by their cytogenetic abnormalities (high risk and standard risk). Patients with 1q gains were shown to have similar outcomes to those without q1 gains when treated with bortezomib plus melphalan and prednisone, followed by lenalidomide and dexamethasone.
Researchers presented results of the randomized, prospective IFM 2013-04 trial that compared the induction treatment regimens of bortezomib/thalidomide/dexamethasone and bortezomib/cyclophosphamide/dexamethasone prior to autologous stem-cell transplant (ASCT) in patients with de novo multiple myeloma (MM).
Filanesib, a kinesin spindle protein inhibitor, has demonstrated promising clinical activity in patients with multiple myeloma refractory to proteasome inhibitors and immunomodulatory drugs. This new combination demonstrated good tolerability and an increased observed response rate compared with carfilzomib alone.
The ENDEAVOR study demonstrated that carfilzomib plus dexamethasone showed a significant improvement in median progression-free survival compared with bortezomib plus dexamethasone. This update examines outcomes in patients in high-risk cytogenetic subgroups.